Initial results from BEACON, a phase 1b/2a dose escalation study of the anti-c-Kit briquilimab antibody in adults with chronic spontaneous urticaria (CSU)

被引：0
|
作者：
Casale, Thomas [1 ]
Tucker, Edwin [2 ]
Yuan, Jinwei [2 ]
Adelman, Daniel [3 ]
Ku, David [2 ]
Marcantonio, Annette [2 ]
Carlos, Patricia [2 ]
Majeed, Sophia [2 ]
Pang, Wendy [2 ]
Maurer, Marcus [4 ]
Metz, Martin [5 ]
机构：
[1] Univ S Florida, Tampa, FL USA
[2] Jasper Therapeut, Redwood City, CA USA
[3] Univ Calif San Francisco, San Francisco, CA USA
[4] Charite, Berlin, Germany
[5] Charite Campus Mitte, Berlin, Germany
来源：
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY | 2025年 / 155卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R392 [医学免疫学];
学科分类号：
100102 ;
摘要：
L24
引用
收藏
页码：AB435 / AB435
页数：1
相关论文
共 50 条
  • [41] PHASE 1B DOSE-ESCALATION STUDY OF SD-101, A NOVEL THERAPEUTIC TLR-9 AGONIST, IN TREATMENT-NAIVE CHRONIC HEPATITIS C PATIENTS
    Cianciara, J.
    Martin, J. T.
    Spellman, M. C.
    JOURNAL OF HEPATOLOGY, 2010, 52 : S126 - S126
  • [42] Efficacy and safety data of AK002, an anti-siglec-8 monoclonal antibody, in patients with multiple forms of uncontrolled chronic urticaria (CU): Results from an open-label phase 2a study
    Altrichter, S.
    Staubach, P.
    Pasha, M.
    Rasmussen, H. S.
    Singh, B.
    Chang, A. T.
    Bernstein, J. A.
    Siebenhaar, F.
    Maurer, M.
    ALLERGY, 2019, 74 : 120 - 120
  • [43] Safety and tolerability of bexicaserin in adolescents and adults with developmental and epileptic encephalopathies: Interim results of the phase 1b/2a PACIFIC Study Open-Label Extension (OLE)
    McLin, D.
    Orevillo, C.
    Le, M.
    Kaye, R.
    EPILEPSIA, 2024, 65 : 449 - 449
  • [44] Clinical Profile of Single-Agent Oprozomib in Patients (Pts) with Multiple Myeloma (MM): Updated Results from a Multicenter, Open-Label, Dose Escalation Phase 1b/2 Study
    Vij, Ravi
    Savona, Michael
    Siegel, David S.
    Kaufman, Jonathan L.
    Badros, Ashraf
    Ghobrial, Irene M.
    Paner, Agne
    Jagannath, Sundar
    Jakubowiak, Andrzej
    Mikhael, Joseph R.
    Kapoor, Prashant
    Neuman, Linda L.
    Lee, Ju RueyJiuan
    Berdeja, Jesus G.
    BLOOD, 2014, 124 (21)
  • [45] OPROZOMIB (OPZ) AND DEXAMETHASONE (DEX) IN PATIENTS (PTS) WITH RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA (RRMM): UPDATED RESULTS FROM DOSE ESCALATION IN A PHASE 1B/2, MULTICENTER, OPEN-LABEL STUDY
    Hari, P.
    Shain, K. H.
    Voorhees, P.
    Gabrail, N.
    Abidi, M.
    Zonder, J.
    Boccia, R.
    Richardson, P. G.
    Neuman, L.
    Wong, H.
    Dixon, S.
    Prada, C. P.
    HAEMATOLOGICA, 2015, 100 : 254 - 255
  • [46] UPDATED RESULTS FROM A MULTICENTER, OPEN-LABEL, DOSE-ESCALATION PHASE 1B/2 STUDY OF SINGLE-AGENT OPROZOMIB IN PATIENTS WITH HEMATOLOGIC MALIGNANCIES, INCLUDING WALDENSTROM MACROGLOBULINEMIA
    Siegel, D.
    Kaufman, J. L.
    Raje, N.
    Mikhael, J.
    Kapoor, P.
    Treon, S.
    Castillo, J.
    Neuman, L.
    Obreja, M.
    Ghobrial, I.
    HAEMATOLOGICA, 2015, 100 : 461 - 461
  • [47] PHASE 1/2 DOSE ESCALATION AND DOSE EXPANSION STUDY OF TRANSCON TLR7/8 AGONIST ALONE OR IN COMBINATION WITH PEMBROLIZUMAB IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMOR MALIGNANCIES: INITIAL RESULTS FROM DOSE ESCALATION
    Davar, Diwakar
    Aghmesheh, Morteza
    Algazi, Alain
    Bajor, David
    Ganju, Vinod
    Laux, Douglas
    Spira, Alexander
    Ahern, Elizabeth
    Grewal, Jaspreet
    Rand, Jamie
    Sweis, Randy
    Karlsson, Jens-Jakob
    Kriegbaum, Mette
    Wu, Yang
    Tran, Tuan-Anh
    Singel, Stina
    Gabrail, Nashat
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A795 - A795
  • [48] TREATMENT OF SLE WITH THE IMMUNOPROTEASOME INHIBITOR KZR-616: RESULTS FROM THE FIRST 4 COHORTS OF THE MISSION STUDY, AN OPEN-LABEL PHASE 1B DOSE ESCALATION TRIAL
    Furie, Richard
    Bomba, Darrin
    Dall'Era, Maria
    Khan, Amber
    Soneira, Miguel
    Parikh, Samir V.
    Maiquez, Adonis
    Moreno, Orlando
    Farmer, M. K.
    Palaniswamy, Kiruthi
    Anderl, Janet
    Wang, Jinhai
    Ruiz, Pedro
    Kirk, Christopher
    JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2020, 26 : 97 - 98
  • [49] Preliminary results from patients with urothelial carcinoma (UC) in a phase 1A/1B study of bgb-A317, an anti-PD-1 monoclonal antibody.
    Sandhu, Shahneen Kaur
    Hill, Andrew Graham
    Gan, Hui Kong
    Friedlander, Michael
    Voskoboynik, Mark
    Barlow, Paula
    Townsend, Amanda Rose
    Song, James
    Zhang, Yun
    Shen, Zhirong
    Qi, Qinzhou
    Desai, Jayesh
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
  • [50] TREATMENT OF SLE WITH THE IMMUNOPROTEASOME INHIBITOR KZR-616: RESULTS FROM THE FIRST 4 COHORTS OF THE MISSION STUDY, AN OPEN-LABEL PHASE 1B DOSE ESCALATION TRIAL
    Furie, R.
    Parikh, S.
    Maiquez, A.
    Khan, A.
    Moreno, O.
    Soneira, M.
    Kirk, C.
    Bomba, D.
    Harvey, K.
    Farmer, M. K.
    ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 : 1482 - 1483
12345